A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10), a disease activity measure distinguish patients with inactive disease, minimal disease activity, moderate disease activity, and high disease activity.
Dr. John Cush RheumNow
2 years 5 months ago
Machine learning analysis of retrosp EHR data (3/20-9/22) on 2+ million showed COVID (5.3%) outcomes in #IMID pts not linked to DMARD or IMID Dx; but rather to age, unvaccinated, & comorbidities (Afib, CAD, CHF, CKD, COPD, CA, liver Dz) https://t.co/aMmJD5P9cc https://t.co/Yy9FuCvol4
A metanalysis shows that social determinants of health adversely impacts patients with lupus nephritis. Lupus nephritis is a significant complication of SLE, often with dramatic increases in morbid and mortal risks. Outcomes are likely to be augmented by social determinants of health, including socio-economic status, and social risk factors.
Positive findings with color Doppler ultrasound were enough to diagnose giant cell arteritis (GCA) accurately without need for confirmation with temporal artery biopsy (TAB), a prospective study indicated.
Dr. John Cush RheumNow
2 years 5 months ago
SLE Faculty Panel Q&A
https://t.co/2OWlhfmKaP https://t.co/jx6MPDtojS
Dr. John Cush RheumNow
2 years 5 months ago
Complex Autoantibody Patterns in RA
https://t.co/WmaXmmP7dY https://t.co/4dFgFEZ84i
Dr. John Cush RheumNow
2 years 5 months ago
NEJM: evolution of pyoderma gangrenosum skin lesions https://t.co/vsgQhsjY5q https://t.co/INrbTIc9kX
Dr. John Cush RheumNow
2 years 5 months ago
Systemic Inflammation and Mortality in RA-ILD
Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with RA-ILD.
https://t.co/Qjtg364Pv7 https://t.co/aTQxTcO6Yv
Dr. John Cush RheumNow
2 years 5 months ago
In 530 #GCA pts, relapses seen in 46%; but severe relapse (ischemi/aortic events) in 3%. Severe GCA relapse pts more likely to be younger at Dx(P=0.02), w/ more limb claudication(< 0.0001), fewer GCA-related cranial Sxs (<0.0001); but not higher mortality https://t.co/k7wgU6oMcn https://t.co/BKOfGmZ27u
Dr. John Cush RheumNow
2 years 5 months ago
FDA issued a drug safety warning linking thiopurine (AZA, 6MP) use in pregnancy & a rare risk of intrahepatic cholestasis of pregnancy (ICP). ICP has been reported in pts w/ CD, UC, or SLE; however thiopurines are not FDA approved for these Dx https://t.co/s37eRuAtQx
Dr. John Cush RheumNow
2 years 5 months ago
Study of f 234 AAV pts. 85 (36%) developed diffuse alveolar haemorrhage. Independent predictors of DAH: 1) Age [OR=1.037); 2) PLT # [OR=0.996]; 3) ESR [OR=1.028]; 4) HgB [OR=0.978]; 5) hematuria [OR=3.77] https://t.co/shI8RPZgcv https://t.co/dmceGvUuyR
Dr. John Cush RheumNow
2 years 5 months ago
Biomarker Predictors of Osteoarthritis
Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic OA. S
https://t.co/z5Tg9pAgqO https://t.co/ltY4rEg9p3 https://t.co/AjCKaUW59X
Dr. John Cush RheumNow
2 years 5 months ago
Very late onset Lupus (>60) is less female, less arthritis/dz activity, lower dsDNA, C3, SSA, SSB and ANA but more Sjogrens & RA? Single clinic study of 845 SLE - jSLE (<18), aSLE (18-49), lSLE (50-60), and vlSLE (>60).vlSLE had lowest survival (20yrs) https://t.co/VwDSArDhrc https://t.co/3pSr0xSCKn
Dr. John Cush RheumNow
2 years 5 months ago
“50% of pts with lupus nephritis are asymptomatic . You have to have a degree of kidney damage before you have proteinuria. Proteinuria does not correlate with intrarenal activity.” – Dr. A Fava #RNL2024 @rheumnow https://t.co/w6UktVozsj
